- Home
- HMR vs NKTR Comparison
HMR vs NKTR Comparison
Compare HMR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMR
- NKTR
- Stock Information
- Founded
- HMR 1984
- NKTR 1990
- Country
- HMR Greece
- NKTR United States
- Employees
- HMR N/A
- NKTR N/A
- Industry
- HMR Marine Transportation
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- HMR Consumer Discretionary
- NKTR Health Care
- Exchange
- HMR Nasdaq
- NKTR Nasdaq
- Market Cap
- HMR 159.3M
- NKTR 160.4M
- IPO Year
- HMR N/A
- NKTR 1994
- Fundamental
- Price
- HMR $1.89
- NKTR $0.72
- Analyst Decision
- HMR Strong Buy
- NKTR Strong Buy
- Analyst Count
- HMR 1
- NKTR 6
- Target Price
- HMR $7.00
- NKTR $4.92
- AVG Volume (30 Days)
- HMR 133.7K
- NKTR 1.9M
- Earning Date
- HMR 01-01-0001
- NKTR 05-08-2025
- Dividend Yield
- HMR N/A
- NKTR N/A
- EPS Growth
- HMR N/A
- NKTR N/A
- EPS
- HMR 96.00
- NKTR N/A
- Revenue
- HMR $28,949,873.00
- NKTR $87,248,000.00
- Revenue This Year
- HMR N/A
- NKTR N/A
- Revenue Next Year
- HMR N/A
- NKTR N/A
- P/E Ratio
- HMR $0.02
- NKTR N/A
- Revenue Growth
- HMR N/A
- NKTR N/A
- 52 Week Low
- HMR $1.45
- NKTR $0.43
- 52 Week High
- HMR $10.04
- NKTR $1.52
- Technical
- Relative Strength Index (RSI)
- HMR N/A
- NKTR 54.57
- Support Level
- HMR N/A
- NKTR $0.61
- Resistance Level
- HMR N/A
- NKTR $0.74
- Average True Range (ATR)
- HMR 0.00
- NKTR 0.06
- MACD
- HMR 0.00
- NKTR 0.01
- Stochastic Oscillator
- HMR 0.00
- NKTR 81.79
About HMR Heidmar Maritime Holdings Corp. Common Stock
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. It is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.